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Background: Transforming growth factor-β (TGF-β)-activated kinase 1 (TAK1) is a key regulator of signal
cascades of TNF-α receptor and TLR4, and can induce NF-κB activation for preventing cell apoptosis and
eliciting inflammation response.
Results: TAK1 inhibitor (TAKI) can decrease the cell viability of murine bone marrow-derived macrophages
(BMDM), RAW264.7 and BV-2 cells, but not dermal microvascular endothelial cells, normal human epidermal
keratinocytes, THP-1 monocytes, human retinal pigment epithelial cells, microglia CHME3 cells, and some
cancer cell lines (CL1.0, HeLa and HCT116). In BMDM, TAKI-induced caspase activation and cell apoptosis were
enhanced by lipopolysaccharide (LPS). Moreover, TAKI treatment increased the cytosolic and mitochondrial
reactive oxygen species (ROS) production, and ROS scavengers NAC and BHA can inhibit cell death caused by TAKI.
In addition, RIP1 inhibitor (necrostatin-1) can protect cells against TAKI-induced mitochondrial ROS production and cell
apoptosis. We also observed the mitochondrial membrane potential loss after TAKI treatment and deterioration of
oxygen consumption upon combination with LPS. Notably TNF-α neutralization antibody and inhibitor enbrel can
decrease the cell death caused by TAKI.
Conclusions: TAKI-induced cytotoxicity is cell context specific, and apoptosis observed in macrophages is dependent on
the constitutive autocrine action of TNF-α for RIP1 activation and ROS production.
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Transforming growth factor-β (TGF-β)-activated kinase 1
(TAK1) is a ubiquitously expressed mitogen-activated
protein kinase kinase kinase and plays a key role in regu-
lating inflammation, immunity, cell differentiation and
death [1–3]. Accumulating evidence indicates that TAK1 is
a key regulator of signal transduction cascades and is
activated by various inflammatory mediators and cytokines
such as transforming growth factor (TGF)-β, tumor
necrosis factor (TNF)-α, interleukin (IL)-1β, CD40 ligand,
toll-like receptor (TLR) ligands, T and B cell receptor* Correspondence: wwllaura1119@ntu.edu.tw
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ing proteins, TAB1 and TAB2/TAB3, as well as by post-
translational modification including ubiquitination and
phosphorylation. In TLR4 signaling, TRAF6 through its E3
ubiquitin ligase activity facilitates the formation of K63
polyubiquitin chains to recruit and activate TAK1 [5]. This
activation then transduces signals for activating down-
stream kinases IKK, p38, and JNK, in turn leading to acti-
vate NF-κB and activator protein-1 (AP-1) to produce the
proinflammatory and anti-apoptosis proteins [4, 6–8]. Con-
sistently the notion implicating TAK1 as a key intermediary
in cell survival is evidenced by observing the embryonic le-
thality associated with multi-tissue defects in germline defi-
cient of TAK1 gene [4]. Subsequent studies in mice with
the conditional ablation of TAK1 in hepatocytes [9], liver
parenchymal cells [10], keratinocytes [11], intestinal epithe-
lial cells [12], dendritic cells [13], and monocytes [14],
further strengthen the cytoprotection role of TAK1.is distributed under the terms of the Creative Commons Attribution 4.0
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logical processes and plays an important role in mediating
survival signaling, apoptosis and necroptosis depending on
the cell types and cellular context [1]. On TNF-α binding,
TNF receptor 1 (TNFR1) undergoes a conformational
change to form TNFR complex I containing TRADD,
receptor-interacting protein (RIP)1, cIAPs, TRAF2 and
TRAF5. RIP1 ubiquitylation by cIAP1 or TRAF2 can re-
cruit the TAK1 to initiate the canonical NF-κB survival
pathway [1, 4, 10, 15]. Upon inhibition of NF-κB signaling,
for example by de-ubiquitylation of RIP1 and loss of cIAPs,
TNFR complex II (TRADD, FADD, caspase 8, RIP1 and
RIP3) can be formed and execute two distinct types of cell
death, apoptosis and necroptosis that compete for each
other and is switched by TAK1 and caspases. Normally,
caspase 8 triggers apoptosis by cleaving RIP1 to inhibit the
pro-survival actions derived from NF-κB signaling, and the
pro-apoptotic protein Bid to generate a truncated form
(tBid) for inducing cytochrome c release and apoptosome
formation. However, when caspase 8 is blocked by pharma-
cological or genetic interventions, RIP1 can recruit RIP3 to
form the RIP1/RIP3 necrosome. Within this necrosome,
RIP1 and RIP3 phosphorylate each other, further stabilizing
the complex and engaging the effector mechanisms of
necroptosis, which is a recently identified programmed cell
death [16, 17]. Necroptosis has been shown to rely on
mitochondrial reactive oxygen species (ROS) production
and disintegration of mitochondrial, lysosomal and plasma
membranes [18–20]. Moreover, necroptosis has been
shown to involve in the pathogenesis of various diseases,
such as ischemic injury, neurodegeneration, viral infec-
tion, liver injury, traumatic brain injury, and severe drug
reaction [21].
Notably, recent studies further demonstrate the role of
TAK1 in controlling the RIP1-dependent apoptosis
triggered by TNFR complex II. Besides inducing NF-
κB-dependent anti-apoptotic mechanisms, an NF-κB-
independent cell survival pathway downstream of TAK1
and involving the regulation of ROS-cIAPs-RIP1-caspase
pathway has been suggested [2, 22, 23]. Moreover, in
mouse embryonic fibroblasts (MEF), TAK1 activity was
shown to be a switch between apoptosis and necroptosis
following TNF-α stimulation [24]. Hyperactivation of
TAK1 possibly through inhibition of caspase-1 leads to
necroptosis in dermal fibroblasts which results in the
delay in wound healing. In contrast, ablation of TAK1
causes RIP1- and caspase-dependent apoptosis in MEF
and monocytes [14, 24]. Since TAK1 is a potential thera-
peutic target of inflammatory disorders and cancer [25], it
is essential to more understand the role of TAK1 in cell
death regulation in different cell types. Moreover, since
the role of TAK1 in controlling RIP1-dependent apoptosis
was just recently raised and demonstrated only in limited
cell types under certain cellular context (e.g. under TAKdeficiency plus treatment with either TNF-α or Smac
mimetic), it is warrant to further elucidate the detailed
regulatory mechanisms underlying this event. Therefore,
in this study using 5Z-7-oxozeaenol (TAKI), which is a
natural product of fungal origin and an irreversible TAK1
inhibitor [26], we found a cell type specific action of TAKI
in apoptosis, and this action occurring in myeloid cells is
dependent on endogenously constitutive TNFR-mediated
RIP1 activation and mitochondrial ROS production.
Methods
Cell culture
Bone marrow-derived macrophages (BMDM) were isolated
from 8–12 week old C57BL/6 mice as we previously
described [27]. Lung cancer CL1.0 cell line was provided by
Dr. Zhixin Yang (National Taiwan University, Taipei,
Taiwan). Murine RAW264.7 macrophages, and other cell
lines were obtained from the American Type Culture
Collection (Manassas, VA, USA). The normal human
epidermal keratinocytes (NHEKs) were prepared as we
previously described according to the Mackay Memorial
Hospital Institutional Review Board (IRB 12MMHIS193)
[28]. The CL1.0, HeLa, BV-2, RAW264.7, J774, A431 and
CHME3 cells were cultured in Dulbecco’s modified Eagle’s
medium (DMEM). The HCT116 and THP-1 cells were
cultured in RPMI 1640 medium. The human retinal pig-
ment epithelial cells (ARPE) were cultured in a 1:1 mixture
of DMEM and Ham’s F12 medium. Human dermal micro-
vascular endothelial cells (DMVEC) were cultured in Vas-
cular Cell Basal Medium containing Kit-VEGF (ATCC®
PCS100 041™). NHEKs were cultured in Keratinocyte-SFM
(Gibco BRL/Invitrogen, Carlsbad, CA) supplemented with
recombinant epidermal growth factor (0.1–0.2 ng/ml)
and bovine pituitary extract (20–30 mg/ml). All culture
media contain 10 % (v/v) heat-inactivated FBS, 100 U/ml
penicillin and 100 μg/ml streptomycin. Cells were incu-
bated at 37 °C in a humidified atmosphere of 5 % CO2 in
air.
Measurement of cell viability by MTT assay and LDH release
After indicated drug treatment, cells (2 × 104/ml) in 96-
well plates were incubated with 1 mg/ml 3-(4,5-dimethyl-
thiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) at
37 °C for 60 min. The culture medium was removed, and
then the formazan granules generated by live cells were
dissolved in DMSO. The net absorbance (OD550 - OD630)
indicating the enzymatic activity of mitochondria and cell
viability was measured. In some experiments, cytotoxicity
was assessed by measuring the release from damaged cells
of the cytosolic enzyme lactic dehydrogenase (LDH). After
treating cells with the indicated agents, LDH activity
present in the culture medium was determined using a
LDH diagnostic kit (Promega, Heidelberg, Germany). The
absorbance values were read at OD490 on a Synergy HT
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VT, USA). Data were expressed as the percentages of total
cellular amount of LDH that was determined by lysing
cells with lysis buffer (0.9 % Triton X-100).
Intracellular ATP assay
Intracellular ATP was determined by CellTiter-Glo® Lu-
minescent Kit (G7571, Promega Heidelberg, Germany)
according to the manufacturer’s protocol. After indicated
drug treatment, medium was replaced with the new one,
and the reagent in the kit was added to lyse the cells.
The plate was gently shaken for 2 min, placed stationary
in the dark for 10 min, and then 150 μl solution was
transferred to a 96-well plate for luminescence detection
using LB96V MicroLumat plus (American Laboratory
Trading, Boston, USA). With background subtraction,
the values were normalized to individual control group
as 100 %.
Intracellular ROS detection
After being treated for the indicated time periods, cells
were collected and washed with PBS twice, then incu-
bated in PBS containing 5 μM DCFH-DA (for detecting
the cytosolic ROS) or MitoSOX red (for detecting super-
oxide in the mitochondria of live cells) for 30 min at
37 °C. After incubation, cells were immediately subjected
to flow-cytometry analysis using the FACScan. The data
were analyzed with the CellQuest program.
Mitochondrial respiration measurement
The oxygen consumption rate (OCR) was measured by
the Extracellular flux analyzer XF24 (Seahorse Bio-
science, Houston, TX, USA). About 50,000 BMDM cells
were plated on laminin-coated XF24 plates and cultured
for 24 h in a 5 % CO2 incubator at 37 °C. Then, the
medium was removed and replaced by 500 μl FX assay
medium (143 mM NaCl, 5.4 mM KCl, 0.8 mM MgSO4,
1.8 mM CaCl2, 0.91 mM Na2HPO4, 2 mM glutamine,
2 mg/ml BSA, 3 mg/l phenol red, and other constitu-
ents, pH 7.4.) The BMDM cells were preincubated for
1 h at 37 °C in normal atmosphere. Stock solutions
(×10) of 1 μg/ml LPS, 1 μM TAKI or LPS plus TAKI
(injection on port A), 10 μg/ml oligomycin (ATP syn-
thase inhibitor in port B), 2.5 μM carbonyl cyanide-p-
trifluoro methoxyphenylhydrazone (FCCP, a mitochon-
drial uncoupler of oxidative phosphorylation in port C),
and 2.5 μM rotenone (an inhibitor of mitochondrial
Complex I in port D) were prepared in FX24 assay
media and loaded into injection ports respectively, then
measurements were obtained at 37 °C.
Statistical evaluation
Values were expressed as the mean ± S.E.M. of at least
three independent experiments, which were performed induplicate. Analysis of variance was used to assess the sta-
tistical significance of the differences, and P value < 0.05
was considered statistically significant.
Ethical approval
The animal experiments were conducted in accordance
with institute regulations after receiving approval from
the Ethics Committee of the National Taiwan University
College of Medicine (No. 20130391).
Results
TAKI induced apoptotic cell death in BMDM
Using MTT assay as the index of cell viability, we found
that TAKI (100 nM) treatment for 4 h can induce cell
death of BMDM. Since LPS is a potent TAK1 and NF-κB
activator in BMDM, we interested to understand whether
TAKI-induced cytotoxicity is affected under LPS treat-
ment. Notably we found that LPS at sub-cytotoxic con-
centration (100 ng/ml) can enhance cell death of TAKI
(Fig. 1a). Measuring intracellular ATP level also showed
the cytotoxic effect of TAKI and lower ATP content under
simultaneous activation of TLR4 (Fig. 1b). To verify the
cell death mode, we determined Annexin V and PI stain-
ing. Results showed that cell population of Annexin V
positive staining, either with or without higher PI staining,
was increased along with the time of TAKI treatment
(Fig. 1c). In agreement with data of MTT and ATP assays,
TAKI-induced increase of Annexin V-positive cell number
was elevated in the presence of LPS (Fig. 1c).
Next using PI uptake for necrosis assessment, we found
the amount of cells with positive PI staining was increased
by TAKI, and was also enhanced in the presence of LPS
(Fig. 1d). Further determining the cell necrotic LDH
release, we found the concentration- (Fig. 1e) and time-
(Fig. 1f) dependent effects of LPS to enhance the TAKI-
induced response. Using TLR4−/− BMDM, we confirmed
the potentiation effect of LPS on TAKI-induced cell death
is resulting from TLR4 activation (Fig. 1g). Given that PI
uptake and LDH release were induced along with the
increased Annexin V staining, it is suggested that the cell
death elicited by TAKI is apoptosis followed by the fast
proceeding to necrosis.
TAKI-induced apoptosis depends on RIP1
Confirming apoptotic feature, TAKI can induce active
caspase 8 and caspase 3 formation, and PARP1 cleavage
(Fig. 2a). Although LPS co-treatment facilitated the down-
regulation of pro-caspase 3 and PARP1, it was hard to
detect the increased cleavage forms of both proteins. We
speculate this is possibly due to the instability of both
cleaved proteins. These results suggest that LPS stimula-
tion can enhance TAKI-elicited apoptotic caspase activa-
tion. Since TAK1 has been shown to regulate autophagy
in breast epithelial cells MCF10A and human cervical
Fig. 1 TAKI induced apoptotic cell death in BMDM. Cells were treated with TAKI (100 nM) and/or LPS (100 ng/ml) for 2, 4 and 6 h. Then cell
viability assessed by MTT assay (a), ATP content assay (b), Annexin V/PI staining (c) and PI uptake (d) was determined. In some experiments for
LDH release assay, TAKI and/or LPS at different concentrations were given to BMDM for 6 h (e), or treating both to BMDM for different time
intervals (f). In (g), wild type (WT) and TLR4−/− BMDM were treated with TAKI (100 nM), LPS (100 ng/ml) or both for 6 h, and LDH activity was
measured. *p <0.05, indicating the significant effect of TAKI or LPS alone on cell death. #p <0.05, indicating the significant potentiation of cell
death by LPS in TAKI-treated cells
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Fig. 2 TAKI-induced cytotoxicity is dependent on RIP1 activity. (a) BMDM were treated with TAKI (100 nM) and/or LPS (100 ng/ml) for indicated
time periods. Cell lysates were collected for immunobloting. (b, c) BMDM were pre-treated with necrostatin-1 (Nec-1, 10 μM) and/or zVAD (20 μM) for
30 min followed by adding TAKI (100 nM) and/or LPS (100 ng/ml) for 6 h. LDH activity in the collected culture medium (b) and amount of Annexin
V/PI positive cells (c) were determined. *p <0.05, indicating the significant effect of TAKI alone. #p <0.05, indicating the significant effects of LPS and
zVAD on the response of TAKI. **p <0.05, indicating the significant inhibition of TAKI-induced cell death by Nec-1
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event occurs in BMDM. When autophagy is activated,
LC3II [LC3-phosphatidylethanolamine (PE)] formation is
prerequisite for autophagosome formation and is regarded
as an autophagy marker [31]. Results of immunobloting
showed no increased effect of TAKI, with or without LPS
co-treatment, on LC3II/LC3I ratio (Fig. 2a).
To characterize the cell death pathway in BMDM, we
examined the role of RIP1. To this end, we pre-treated
cells with 10 μM necrostatin-1 (Nec-1, a selective RIP1 in-
hibitor) and found that Nec-1 can protect cells from
TAKI-induced LDH release (Fig. 2b) and Annexin V stain-
ing (Fig. 2c). Such protection was also observed in cells
with LPS and TAKI co-treatment. Since non-selective cas-
pase inhibitor zVAD was reported to sensitize macro-
phages and MEF for RIP1-dependent necroptosis [32–34],
we further treated macrophages with zVAD to clarify the
cell death effects of TAKI. Results revealed that zVADitself did not affect cell viability (Fig. 2b, c), but its pres-
ence further potentiated the TAKI-induced cytotoxicity.
Nevertheless when enhanced cytotoxicity was already in-
duced by TAKI + LPS, zVAD no longer increased the cell
toxicity. Moreover, the death induced by TAKI + LPS, no
matter in the presence or not of zVAD, was diminished by
Nec-1 (Fig. 2b, c). These results suggest the involvement
of RIP1 in TAKI-induced cell death regardless of the
presence of LPS or zVAD.
TAKI-induced cytotoxicity depends on ROS
Since ROS play an important role in apoptosis and necro-
sis, we used DCFH-DA and MitoSOX staining to deter-
mine cytosolic and mitochondrial ROS levels respectively.
The data revealed that both TAKI (100 nM) and LPS
(100 ng/ml) can increase cytosolic ROS level (Fig. 3a) with
similar extent, and their co-treatment was non-additive
(Fig. 3a). Compared to the early onset (30 min) of ROS
Fig. 3 TAKI-induced cytotoxicity is dependent on mitochondrial ROS. (a, b) BMDM were treated with TAKI (100 nM), LPS (100 ng/ml), or both for
indicated time periods. (c, d) BMDM were pre-treated with Nec-1 (10 μM) or zVAD (20 μM) for 30 min before the addition of TAKI, LPS or both for
6 h. The cytosolic and mitochondrial ROS production were determined by DCFH-DA (a, c) and MitoSOX (b, d), respectively, and we used the levels under
vehicle treatment as the control. (e, f) BMDM were pre-treated with NAC (5 mM) or BHA (150 μM) for 30 min followed by TAKI and/or LPS stimulation.
After 6 h incubation, LDH release was determined (e) and after 4 h drug treatment, Annexin V/PI staining (f) was determined. *p <0.05,
indicating significant effects of TAKI or LPS alone. #p<0.05, indicating the significant potentiation of TAKI-induced responses by LPS. **p<0.05, indicating
significant inhibitory effects of Nec-1, NAC and BHA on the responses induced by TAKI, either in the absence or presence of LPS
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observed at 6 h after TAKI treatment. Although LPS alone
did not cause significant mitochondrial ROS production,
its co-treatment with TAKI led to an enhancement of
mitochondrial ROS production in terms of its onset andextent (Fig. 3b). Due to the apparent cytotoxicity, we did
not detect a sustained mitochondrial ROS increase at 6 h
in TAKI + LPS group. Accordingly we tested the effects of
Nec-1, NAC (a general antioxidant through production of
intracellular GSH), BHA (a ROS scavenger) and zVAD on
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ROS production is much earlier than that of mitochon-
drial ROS, and RIP1-mediated mitochondrial ROS is
implicated in necroptotic cell death [35], we wonder if the
early increased cytosolic ROS is also mediated by RIP1. As
a result, Nec-1 can reduce the mitochondrial but not cyto-
solic ROS increase induced by TAKI (Fig. 3c, d). On the
other hand, zVAD did not cause any changes in this aspect
(Fig. 3c, d). In addition, NAC and BHA can markedly
reduce LDH release induced by TAKI/LPS (Fig. 3e), and
NAC also reduced the amount of Annexin V positive cells
in response to TAKI (Fig. 3f). These results suggest the
prerequisite role of mitochondrial ROS production trig-
gered by RIP1 rather than cytosolic ROS in TAKI-induced
cell death.
No contribution of IKK and MAPKs to TAKI-induced
cell death
Apart from RIP1, we wonder the roles of MAPKs and IKK
in TAKI-induced cell death. Immunobloting data revealed
the abilities of TAKI to inhibit TAK1, IKK, ERK, p38 and
JNK activation induced by LPS (Fig. 4a). Since TAKI can
inhibit but not abolish IKK and MAPKs activation under
LPS stimulation, we wondered if these kinases are involved
to regulate cell death mechanisms under TAKI and/or LPS
stimulation. Then we tested the effects of BMS345541,
SB203580, SP600125, and U0126, inhibitors of IKK, p38,
JNK and ERK, respectively, on TAKI-induced cell death.
As shown in Fig. 4b, BMS345541 treatment alone can
induce moderate cell death and this effect was further
enhanced by LPS and TAKI. In contrast, MAPKs inhibitors
failed to affect the death induced by TAKI, either in the
presence or absence of LPS (Fig. 4b).Fig. 4 TAKI inhibits LPS-induced IKK, JNK, p38 and ERK activation. (a) BMDM
time intervials, and then immunobloting against specific proteins was conduc
(10 μM), SP600125 (10 μM), or U0126 (10 μM) for 30 min, followed by LPS (10
culture medium was then determined. *p<0.05, indicating significant effect
TAKI-induced responses by LPS. **p<0.5, indicating significant potentiatTAKI-induced cell death involves mitochondria dysfunction
Since apoptosis is characterized as a consequence of
mitochondrial dysfunction, we interested to understand
if TAKI afffects the functions of mitochondria. First, we
found that TAKI treatment caused the loss of mitochon-
drial membrane potential, which was unchanged by LPS,
but was reversed by Nec-1 (Fig. 5a). Notably as the
increased cell death response shown above, zVAD aug-
mented mitochondrial membrane potential loss caused
by TAKI/LPS (Fig. 5a). Next, we analyzed mitochondrial
oxygen consumption rate (OCR) which reflects overall
metabolic activity of mitochondria. As shown in Fig. 5b,
TAKI treatment can gradually decrease OCR, while LPS
itself did not induce significant OCR change. Neverthe-
less LPS co-treatment can accelerate the effect of TAKI.
After drug treatment for 2 h, we added standard agents
oligomycin, FCCP and rotenone to determine the mito-
chondrial respiration functions. We found oligomycin
can rapidly decrease OCR levels in control and LPS
groups, but not in TAKI and TAKI/LPS groups when
their OCR level was markedly decreased. Meanwhile,
unlike the general effects of FCCP and rotenone in con-
trol and LPS groups, both mitochondrial tested agents
also cannot alter OCR in cells treated with TAKI, either
with or without LPS (Fig. 5b).
Intrinsic action of TNF-α contributes to TAKI-induced
cell death
Since TNF-α has been shown to induce cell death of vari-
ous features depending on the cellular context, we won-
dered its involvement in TAKI-treated macrophages. Using
neutralizing TNF-α antibody and enbrel (soluble TNF-α
receptor), we found that the cell death induced by TAKI,were treated with LPS (100 ng/ml), TAKI (100 nM) or both for indicated
ted. (b) BMDM were pretreated with BMS345541 (3 μM), SB230580
0 ng/ml), TAKI (100 nM) or both for 6 h. The LDH activity released in the
s of TAKI alone. #p<0.05, indicating the significant potentiation of
ion of TAKI or LPS response by BMS345541
Fig. 5 TAKI-induced cell death involves mitochondrial dysfunction. (a) BMDM were treated with 20 μM zVAD or 10 μM Nec-1 for 30 min, followed
by TAKI (100 nM) and/or LPS (100 ng/ml) for 6 h. Then mitochondria membrane potential was detected. *p <0.05, indicating significant reduction
of mitochondrial membrane potential caused by TAKI. **p <0.05, indicating significant potentiation or inhibiion of mitochondrial membrane potential
loss by zVAD and Nec-1, respectively. (b) The mitochondrial metabolism was assessed by using the seahorse XF24 to measure the oxygen consumption
rate (OCR). BMDM were treated with LPS (100 ng/ml), TAKI (100 nM), or LPS plus TAKI at 32 min as indicated with arrow. The inhibitor of ATP synthase,
oligomycin (10 μg/ml) was added to discriminate ATP-linked respiration and proton leak. After adding an uncoupler of mitochondrial oxidative
phosphorylation, FCCP (2.5 μM), OCR was raised to the maximal respiratory capacity. Finally rotenone (2.5 μM) was added to block the electron transport
chain of oxidative phosphorylation
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both treatments (Fig. 6a). Accordingly enbrel can reduce
cytosolic and mitochondrial ROS production caused by
TAKI alone (Fig. 6b, c), and LPS-induced cytosolic ROS
increase was also diminished by enbrel (Fig. 6b). These
findings suggest that autocrine or paracrine action of TNF-
α is involved in TAKI-induced ROS production and subse-
quent cytotoxicity. Next, the TNF-α production was deter-
mined by ELISA in order to correlate with cell death
response. Surprisingly althoughTNF-α antibody and enbrel
can abrogate TAKI-induced cell death and ROS produc-
tion, no significant increase of TNF-α release under TAKI
treatment was found. Stimulating macrophages with LPS
as expected increased TNF-α production, and this effect
was abrogated by the co-treatment with TAKI (Fig. 6d).Besides TNF-α, we also wondered the role of type I IFNs
in cell death, as IFNs have been shown to regulate cell
death in macrophages [36]. As shown in Fig. 6a, antagonis-
tic IFN antibody had minimal effect on TAKI-induced cell
death. These results all together suggest that the intrinsic
and constitutive action of TNF-α is prerequisite for TAKI-
induced ROS production and the subsequent cell death.
TAKI-induced cell death exhibits the cell type specificity
Apart from BMDM, we also tested the effects of TAKI in
other murine macrophages (RAW264.7 and J774) and
microglial (BV-2) cell lines. Using necrotic marker LDH re-
lease as index, we found TAKI treatment also significantly
induces cell death in these cell types with BV-2 displaying
the prominent extent (Fig. 7a). Consistently Nec-1 and
Fig. 6 Intrinsic autocrine action of TNF-α contributes the TAKI-induced cell death. (a) BMDM were pre-treated with enbrel (10 μg/ml), control IgG
(1 μg/ml), TNF-α Ab (1 μg/ml) or IFN-Ab (1 μg/ml) for 30 min, and then treated with TAKI (100 nM) and/or LPS (100 ng/ml) for 6 h. Cell culture
medium was used to determine LDH release. (b, c) BMDM were pre-treated with enbrel (10 μg/ml) for 30 min followed by TAKI and LPS for indicated
intervals, and then cytosolic ROS (b) and mitochondrial ROS (c) were determined. (d) BMDM were treated with LPS (100 ng/ml), TAKI (100 nM) or both
for indicated time intervials, and then the medium was collected to determine TNF-α production. *p <0.05, indicating significant effects of TAKI and/or
LPS. #p <0.05, indicating significant inhibition of LPS-induced TNF-α release by TAKI (d) or significant enhancement of TAKI-induced LDH release by LPS
(a). **p <0.05, indicating significant inhibition of TAKI- and/or LPS-induced responses by enbrel or TNF-α Ab
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death in terms of MTT (Fig. 7b) and ATP assays (Fig. 7c).
Notably zVAD treatment can reverse the cytotoxicity of
TAKI in BV-2 cells, but not in RAW264.7 cells. In order to
understand the cytotoxicity effect of TAKI is general or
not, we examined several cell types. We found that TAKI
at concentrations up to 100 nM failed to alter the cell
viability in human THP-1 monocytes, THP-1-derived mac-
rophages, and CHME, 3 microglia. Neither normal human
epidermal keratinocyte (NHEK), retinal pigment epithelial
cells (ARPE), dermal microvascular endothelial cells
(DMVEC) or cancer cells like A431 squamous cell carcin-
oma, CL1.0 lung cancer, HeLa cervical cancer, and
HCT116 colon cancer was affected by TAKI (Fig. 7a, d, e).
To clear if less intrinsic TNF-α action made such suscepti-
bility difference, we co-treated TNF-α (10 ng/ml) together
with TAKI in these non-responsive cell types. As a result,
TAKI still cannot induce cytotoxicity upon TNF-α co-
treatment by either MTT (Fig. 7d) or ATP assays (Fig. 7e).
After observing this, we wondered if distinct expression
level of endogenous TNFR determines the susceptibility in
response to TAKI + TNF-α. We thus determined the basal
level of TNFR in these cell types. Immunobloting datarevealed that BV-2, HCT116 and NHEK expressed higher
and comparatively equivalent level of TNFR1, RAW264.7,
A431 and ARPE expressed moderate amount, and BMDM
expressed the lowest amount (Fig. 7f). Since TNFR1
expression level does not correlate to the susceptibility of
TNF-α-dependent cytotoxicity, we suggest it is the cellular
context rather than TNF-α signaling determines the cell
viability in response to TAKI.
Discussion
Given that TAK1 exerts multifaceted functions in con-
trolling cell fate and inflammatory responses, targeting
TAK1 for inflammatory disorders and cancer has raised
great attention. The therapeutic potential of TAKI in
enhanced chemotherapeutic efficacy might result from
its potent inhibition of the IKK-NF-κB pathway, potenti-
ation of ROS and caspase activity [37–39]. In this aspect,
previous studies demonstrated the effectiveness of TAK1
inhibition or deficiency in skin cancer [40], multiple lymph-
oma [41], KRAS-dependent colon cancers [42], breast can-
cer [37] and cervical cancer [38]. Moreover, a TAKI closely
analog, E6201 is currently in phase II clinical trials for the
treatment of melanoma [43], and may be useful for
Fig. 7 TAKI-induced cell death exhibits the cell type specificity, and less susceptibility is not due to deficiency of TNF-α action. (a) RAW264.7, J774,
BV-2, THP-1 monocyte, THP-1 macrophage differentiated by PMA (10 nM, 24 h), CHME3, DMVEC, CL1.0 and HeLa were treated with the indicated
concentrations of TAKI for 6 h. Then LDH release to culture medium was measured. (b, c) In RAW264.7 and BV-2 cells, necrostatin-1 (Nec-1,
10 μM), enbrel (10 μg/ml) or zVAD (20 μM) was treated for 30 min before the administration of TAKI (100 nM) for 6 h. (d, e) A431, ARPE, HCT116
and NHEK cells were treated with TAKI (100 nM) and TNF-α (10 ng/ml) for 6 h. MTT (b, d) and ATP assays (c, e) were conducted to measure cell viability.
*p<0.05, indicating significant cell death induced by TAKI. **p<0.05, indicating significant inhibition of TAKI-induced cell death by Nec-1, enbrel or zVAD.
(f) TNFR protein expression in various cell types was compared by immunobloting
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neuroprotective effects of TAK inhibition for stroke,
traumatic brain injury and neurodegenerative diseases are
associated with a reduced activation of JNK that leads to
inflammation and apoptosis [46–48].According to its multifaceted signaling functions as
mentioned above, TAK regulation of cell viability is be-
lieved to be cell type and cell context dependent. Since
macrophages play a major role in acute inflammatory
responses in various tissues and diseases [49], and TAK1
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[2, 50, 51], in this study we used macrophages as the cell
model to deep in the death regulating mechanisms and
signaling pathways controlled by TAK1. Our present data
showed that TAKI can induce a dramatic cell death in pri-
mary BMDM. Different from previous finding showing the
delayed onset of spontaneous cell death in TAK1−/−
BMDM (around 45 % cell death at 4 day) [50]. TAKI-
induced cell death in BMDM is of rapid onset (around
60 % cell death at 6 h treatment). Currently we do not have
clear explanation for this difference, but effects of TAK1
gene deletion on in vitro macrophage differentiation and/
or some cellular adaptive regulation cannot be excluded. In
our study, we found the death caused by TAKI in BMDM
is of caspase-dependent apoptosis mode. The supporting
evidence of this notion includes the appearance of apop-
totic landmark Annexin V (Fig. 1c), and activation of cas-
pases 8 and 3 (Fig. 2a). Here we rule out the involvement
of LC3 dependent autophagy or PARP1 dependent cell
death mode (i.e. parthanatos) in this action, because TAKI
cannot trigger LC3II increase (Fig. 2a) and its induced cell
death is not affected by PARP1 inhibitor (data not shown).
So our result is in agreement with previous report showing
apoptosis occurring in TAK1−/− BMDM [50]. A study
reported by Morioka et al. also showed that ablation of
TAK1 in MEF led to caspase-dependent apoptosis [24].
This study for the first time shows the ability of TAK
inhibitor alone to induce RIP1-dependent apoptosis,
unlike the case requiring exogenous TNF-α to trigger
RIP1-dependent apoptosis in MEF with TAK1-deficient or
inhibition condition [52]. Another interesting finding of
our study is that constitutive TNFR signal through auto-
crine loop plays an important role to control the death
action of TAKI in BMDM, RAW264.7 macrophages and
BV-2 microglia. AlthoughTAKI alone is not able to change
basal TNF-α production (Fig. 6d), TAKI-induced ROS pro-
duction (Fig. 6b, c) and cell death (Fig. 6a) were abrogated
by enbrel and neutralizing antibody of TNF-α. These find-
ings indicate the crucial determinant of autocrine factor
TNF-α to timely control the cell fate in macrophages and
microglia. Even lower amount of TNF-α secreted at resting
state is sufficient to render such death regulation action.
Indeed as previously reported, depending on the statuses
of caspase, RIP1 and TAK1 activity, exogenous TNF-α can
mediate cell survival or various modes of cell death [2].
Thus our current findings support the complexity of TNFR
signaling pathways in coordination with TAK1 activity to
timely control the cell fate. Moreover, we for the first time
to strengthen the key role of constitutive and autocrine ac-
tion of TNF-α in controlling macrophages and microglia
survival. Such intrinsic and quiescent function of TNF-α
can be unmasked and become sensitized to impact cellular
response when TAK1-dependent protection signals and
functions are severely impaired.In this study using TAK inhibitor we demonstrated the
cell type specificity for TAKI-induced cytotoxicity. We
found TAKI itself can induce cell death in murine macro-
phages (BMDM, RAW264.7, J774) and microglia (BV-2),
but not in cancer cells (CL1.0, HeLa, HCT116, A431), hu-
man THP-1 monocytes, human CHME3 microglia, and
primary normal cells (NHEK, ARPE and DMVEC) (Fig. 7).
These data strongly suggest that TAK-dependent cell sig-
naling and molecular events in regulating cell viability are
cell type specific. In addition, although TNFR signaling as
discussed above is important to mediate TAKI-induced
cell death in BMDM, RAW264.7 and BV-2, it is not the
major factor to explain why there is no death response to
TAKI in other cell types. This is because constitutive
TNFR1 level in various cell types does not correlate to the
cell death susceptibility in response to TAKI plus TNF-α
(Fig. 7a, e, f ). Although TNFR1 rather than TNFR2 is
known as the major receptor for TNF-α-induced signaling
and cellular functions, our current study still cannot
exclude the potential role of TNFR2 in controlling the cell
viability of macrophages and microglia in response to
TAKI. Therefore, it is the distinct cellular context rather
than TNF-α signals via TNFR1 alone to determine the cell
susceptibility to TAKI.
Previous studies conducting in TAK1 deletion cell
models have demonstrated the role of ROS accumulation
for cell death [53, 54]. In our study using TAKI we simi-
larly observed the increased cytosolic and mitochondrial
ROS production from TNFR signals in BMDM (Fig. 6b, c).
Moreover, RIP1 inhibition by necrostatin-1 only reduces
mitochondrial but not cytosolic ROS elevation (Fig. 3c, d).
TNFR1 activation has been shown to activate NADPH oxi-
dase for cytosolic ROS production, which causes cIAP pro-
tein depletion and activation of RIP1-dependent caspase-8
[2]. Besides activating caspase-8, RIP1 activation also leads
to ROS production in mitochondria [52]. Based on these
findings we suggest that TAK inhibition can unmask
intrinsic TNFR signal for the rapid initiation of cytosolic
ROS production, which in turn triggers RIP1 activation
and late mitochondrial ROS production. Accordingly we
suggest the enhanced cell death upon LPS co-treatment is
through increased RIP1-dependent mitochondrial ROS
production (Fig. 3b). Previously TLR4 activation by LPS
was shown to activate RIP1 through TRIF signaling path-
way [55]. Similar to TNF-α, NO has been shown to induce
programmed cell death in endothelial cells, and both RIP1
and ROS are involved [56]. Herein, we explored the
possible role of NO in TAKI-elicited cell death in BMDM.
We found that treatment with iNOS inhibitor L-NAME
did not affect cell death induced by TAKI, either in the
presence or absence of LPS (data not show). In addition,
our data suggest the death mechanism caused by TAKI is
independent of IKK, because we observed the additive
cytotoxicity between TAKI and IKK inhibitor (Fig. 4b).
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been shown to switch cell death from apoptosis to either
autophagic cell death or necroptosis [14, 32–34, 57]. Not-
ably the induction of necroptosis by caspase inhibitor in
macrophages and MEF is also RIP1- and TNFR-dependent
[14, 32–34]. In our study, zVAD treatment cannot block
TAKI-induced cell apoptosis in BMDM and RAW264.7
macrophages (Fig. 7b, c), but an even more increased cell
death was observed in BMDM (Fig. 2c). Such cell death
under zVAD treatment in BMDM still depends on RIP1
(Fig. 2b, c). Therefore we suggest zVAD co-treatment can
drive cells proceeding a RIP1-dependent but caspase-
independent apoptosis. Supporting this suggestion, under
caspase inhibition mitochondrial cell death resulting from
loss of respiration, but not from cytotoxic protein release
has been reported [58]. Therefore it is still necessary to ex-
plore the death mechanism in details under TAKI + zVAD
treatment. It is also needed to elucidate the mechanisms
underlying the partial protective effect of zVAD in TAKI-
treated BV-2 cells, which is unlike the effects seen in
BMDM and RAW264.7 cells. Moreover whether autoph-
agy is involved in TAKI + zVAD-induced cell death in
BMDM needs further investigation.
Taken together, we for the first time demonstrate TAKI-
induced cytotoxicity is cell context specific and depends
on the endogenously constitutive TNFR signaling. An
IKK-independent cell survival pathway downstream of
TAK1 is essential for macrophages to prevent apoptosis
signal induced by autocrine TNF-α through RIP1-ROS-
caspase pathway. All these results highlight the complexity
of cell death regulation in macrophages in viewing the
functional balance of molecules among TNFR, TAKI,
RIP1 and caspases. Notably, since TAK inhibition is under
drug development for sensitizing chemotherapy in cancer
patients and for several inflammation-associated diseases,
our current findings are warrant in considering the pros
and cons for targeting TAK in disease treatment.
Conclusion
TAK1 is involved to regulate cell survival. Inhibition of
TAK1 leading to cell death is cell context specific. In mur-
ine macrophages, TAKI-induced apoptosis is dependent
on the constitutive autocrine action of TNF-α, RIP1activa-
tion and ROS production.
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